Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1905 in Chronic Rhinosinusitis With Nasal Polyps
NCT05891483Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1905 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Hengrui Therapeutics. Started Sep 2023; status: completed.
02
Drugs
SHR-1905
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05891483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891483.